Sign up to save your podcasts
Or
Share Building New Zealand's RNA capabilities
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Building New Zealand's RNA capabilities
Scientists had long been exploring RNA technology as a way to make vaccines before it had it’s breakout appearance during the Covid-19 pandemic.
Since then, interest in the potential uses of RNA to make vaccines and disease treatments has bloomed.
In late 2023 a government-funded platform began work to enhance New Zealand’s capacity to design and make RNA. Three years in, how is the platform going?
Sign up to the Our Changing World monthly newsletter for episode backstories, science analysis and more.
Learn more:
- RNA interference (RNAi) technology is being investigated to help honey bees fight off the varroa mite.
- US based Dyne Therapeutics conducted a clinical trial study of their RNA-based therapeutic for myotonic dystrophy in New Zealand.
- Our Changing World covered how the new RNA vaccine tech works in 2021.
- Dr Lisa Connor spoke to RNZ’s health reporter Ruth Hill last August after the US made funding cuts to their RNA vaccine research.
Guests:
- Dr Lisa Connor, Malaghan Institute of Medical Research
- Dr Rebecca McKenzie, Malaghan Institute of Medical Research
Go to this episode on rnz.co.nz for more details
View all episodes
By RNZScientists had long been exploring RNA technology as a way to make vaccines before it had it’s breakout appearance during the Covid-19 pandemic.
Since then, interest in the potential uses of RNA to make vaccines and disease treatments has bloomed.
In late 2023 a government-funded platform began work to enhance New Zealand’s capacity to design and make RNA. Three years in, how is the platform going?
Sign up to the Our Changing World monthly newsletter for episode backstories, science analysis and more.
Learn more:
- RNA interference (RNAi) technology is being investigated to help honey bees fight off the varroa mite.
- US based Dyne Therapeutics conducted a clinical trial study of their RNA-based therapeutic for myotonic dystrophy in New Zealand.
- Our Changing World covered how the new RNA vaccine tech works in 2021.
- Dr Lisa Connor spoke to RNZ’s health reporter Ruth Hill last August after the US made funding cuts to their RNA vaccine research.
Guests:
- Dr Lisa Connor, Malaghan Institute of Medical Research
- Dr Rebecca McKenzie, Malaghan Institute of Medical Research
Go to this episode on rnz.co.nz for more details